Symplicity G3
Payments companies reported to CMS as associated with Symplicity G3. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Symplicity G3, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Symplicity G3
These are the largest totals companies reported as associated with Symplicity G3. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Bloch | Reno, NV | Internal Medicine | $77,053.83 |
| Jeremy Bock | Leesburg, VA | Interventional Cardiology | $72,573.27 |
| Taisei Kobayashi | Philadelphia, PA | Interventional Cardiology | $71,322.68 |
| Barry Bertolet | Tupelo, MS | Cardiovascular Disease | $70,233.91 |
| Tiffany Randolph | Greensboro, NC | Cardiovascular Disease | $47,830.37 |
| Raymond Townsend | Philadelphia, PA | Nephrology (Internal Medicine) | $45,270.84 |
| Atul Chugh | Indianapolis, IN | Cardiovascular Disease | $45,133.39 |
| Kamal Gupta | Kansas City, KS | Interventional Cardiology | $39,029.70 |
| Thomas Todoran | Pawleys Island, SC | Interventional Cardiology | $38,890.15 |
| Maria Delgado - Lelievre | Miami, FL | Internal Medicine | $38,719.06 |
Prescribed Symplicity G3?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.